Genomics, a science-led TechBio company, has extended its drug target discovery and validation collaboration with Vertex Pharmaceuticals by four years. The agreement builds on an existing eight-year partnership that began in 2018 and focuses on using human genetics to support drug discovery and precision medicine development.
Under the extended collaboration, scientists from both companies will continue working together to identify and validate novel drug targets using human genetic data. The research will also focus on biomarker selection for precision medicines and improving understanding of how human genetic variations influence diseases with significant unmet medical needs.
The collaboration aims to use genetic insights to identify disease mechanisms and support the development of potential new therapies. According to the companies, the partnership has demonstrated the application of human genetics in identifying and validating drug targets for the development of new medicines.
The extended agreement has a total potential contract value exceeding USD 220 million, subject to the achievement of specified research, development, regulatory and commercial milestones. It also includes tiered royalties on future net sales of any products developed through the collaboration.
Mark Bunnage, Executive Vice President and Chief Scientific Officer at Vertex Pharmaceuticals, said human genetics and an understanding of disease biology remain central to the company's drug discovery and development approach. He noted that Genomics had been a research partner throughout the collaboration, contributing genetic insights and data science capabilities.
Professor Sir Peter Donnelly, Co-founder and Chief Executive Officer of Genomics, said the extended partnership would allow both companies to expand the use of human genetics in identifying drug targets and biomarkers for precision medicine development.
Genomics uses large-scale genetic and health data alongside proprietary analytical tools to support drug discovery and research. Its database includes more than 45,000 Genome-Wide Association Studies (GWAS), while its research teams have identified over 100 potential drug targets across diseases including cancer, heart disease and diabetes.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy